Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma


Selskabsmeddelelse

Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Genmab A/S

MEDDELELSE
ID:
123599
Type:
Intern viden
Sprog:
Engelsk
Dokument(er):

 
 

TIDSPUNKTER
Offentliggjort:
31.07.2020 | 21:38:12
Registrering:
31.07.2020 | 21:38:16

UDSTEDER
Virksomhed:
Genmab A/S
CVR-nr:
LEI:
529900MTJPDPE4MHJ122

INDBERETTER
Virksomhed:
GlobeNewswire
CVR-nr.:
UK-02775270



Se den originale selskabsmeddelelse hos Finanstilsynet

Find og læs selskabsmeddelelser fra hele Danmark

Scroll til toppen